Home・Список акций・Merck & Co Inc.

Merck & Co Inc.

Открыт

СекторЗдравоохранение

127.89 0.42

Купить Продать

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

125.21

Макс.

129.94

Ключевые показатели
By Trading Economics
Доход	-7.2B -4.2B
Продажи	-114M 16B
P/E Средняя по отрасли	36.834 64.641
Прибыль на акцию	-1.28
Дивидендная доходность	2.5
Рентабельность продаж	-26.053
Сотрудники	73,000
EBITDA	-6.4B -2B

Рекомендации
By TipRanks
Рекомендации	Покупка
Прогноз на 12 месяцев	+7.18% upside

Дивиденды
By Acuity
Дивидендная доходность Средняя по отрасли	2.50% 2.31%
Следующий отчет о доходах	4 авг. 2026 г.
Дата следующей выплаты дивидендов	7 окт. 2026 г.
Следующая эксдивидендная дата	15 сент. 2026 г.

Рыночная статистика
By TradingEconomics
Рыночная капитализация	35B 307B
Предыдущая цена открытия	127.47
Предыдущая цена закрытия	127.89

Новостные настроения

By Acuity

21%

79%

48 / 340 Рейтинг в Healthcare

Merck & Co Inc. График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

3 авг. 2026 г., 20:03 UTC

News

Social Media

Merck & Co Inc shares are lower as the company prepares for Q2 earnings on August 4, despite reporting $16.29 billion in last quarter revenues.

31 июл. 2026 г., 23:16 UTC

Merck & Co Inc shares are higher in after-market hours, maintaining a position near the upper end of their one-month range amid varied broader market performance.

30 июл. 2026 г., 20:09 UTC

Merck & Co Inc shares are declining, with no specific news identified. Broader market volatility is influenced by mixed economic signals and jobless claims.

29 июл. 2026 г., 23:41 UTC

Merck & Co Inc shares are lower in after-market hours, driven by weakness in the Pharmaceuticals sub-sector. The stock remains above its 20-day moving average.

28 июл. 2026 г., 23:01 UTC

Merck & Co Inc shares are higher in after-market hours, maintaining stability above the 20-day moving average and near the upper end of their one-month range.

27 июл. 2026 г., 20:06 UTC

Social Media

Merck & Co Inc shares are lower, testing the $132 level amid broader market declines and declining oil prices impacting Treasury yields ahead of the Fed meeting.

24 июл. 2026 г., 18:56 UTC

News

Social Media

Merck & Co Inc. announced a strategy to enhance access to its HIV prevention drug Alimatravir across 129 countries, boosting shares during Friday's session.

22 июл. 2026 г., 19:46 UTC

Social Media

Merck & Co Inc shares are higher, supported by strong contract performance valued at $1,000. The stock remains near its one-month high amid broader market challenges.

21 июл. 2026 г., 19:56 UTC

News

Social Media

Merck & Co. Inc. shares are rising following positive Phase 3 trial results for its once-weekly oral HIV treatment regimen, islatravir and lenacapavir.

20 июл. 2026 г., 20:02 UTC

Social Media

Merck & Co. shares are lower as the pharmaceutical sector faces pressure. The company plans to price Lipfendra at $10.50 per day.

Сравнение c конкурентами

Изменение цены

Merck & Co Inc. Прогноз

Целевая цена

By TipRanks

7.18% рост

Прогноз на 12 месяцев

Средняя 136.94 USD 7.18%

Максимум 155 USD

Минимум 100 USD

Основано на мнении 18 аналитиков Wall Street, спрогнозировавших целевые цены для Merck & Co Inc. на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Покупка

18 ratings

Покупка

Удержание

Продажа

Основано на мнении 18 аналитиков, присваивавших рейтинги акциям Merck & Co Inc. – Данные за последние 3 месяца.

Настроения

By Acuity

48 / 340Рейтинг в Здравоохранение

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

О компании Merck & Co Inc.

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. vIt has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications. It also has licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova. The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.